Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Deferred Taxes (2024 - 2025)

Theravance Biopharma (TBPH) has disclosed Deferred Taxes for 2 consecutive years, with $30000.0 as the latest value for Q4 2025.

  • Quarterly Deferred Taxes rose 100.46% to $30000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$11.5 million through Dec 2025, down 52.11% year-over-year, with the annual reading at -$11.5 million for FY2025, 52.11% down from the prior year.
  • Deferred Taxes for Q4 2025 was $30000.0 at Theravance Biopharma, down from $994000.0 in the prior quarter.
  • The five-year high for Deferred Taxes was $994000.0 in Q3 2025, with the low at -$10.7 million in Q2 2025.